AU2016306907A1 - A transglutamine tag for efficient site-specific bioconjugation - Google Patents

A transglutamine tag for efficient site-specific bioconjugation Download PDF

Info

Publication number
AU2016306907A1
AU2016306907A1 AU2016306907A AU2016306907A AU2016306907A1 AU 2016306907 A1 AU2016306907 A1 AU 2016306907A1 AU 2016306907 A AU2016306907 A AU 2016306907A AU 2016306907 A AU2016306907 A AU 2016306907A AU 2016306907 A1 AU2016306907 A1 AU 2016306907A1
Authority
AU
Australia
Prior art keywords
seq
tyfqayg
antibody
amino acid
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016306907A
Other languages
English (en)
Other versions
AU2016306907A9 (en
Inventor
Ulrich Betz
Harald Kolmar
Birgit Piater
Vanessa SIEGMUND
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2016306907A1 publication Critical patent/AU2016306907A1/en
Publication of AU2016306907A9 publication Critical patent/AU2016306907A9/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2016306907A 2015-08-07 2016-08-04 A transglutamine tag for efficient site-specific bioconjugation Abandoned AU2016306907A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15180278.2 2015-08-07
EP15180278 2015-08-07
PCT/EP2016/001344 WO2017025179A1 (en) 2015-08-07 2016-08-04 A transglutamine tag for efficient site-specific bioconjugation

Publications (2)

Publication Number Publication Date
AU2016306907A1 true AU2016306907A1 (en) 2018-03-29
AU2016306907A9 AU2016306907A9 (en) 2019-07-25

Family

ID=53785570

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016306907A Abandoned AU2016306907A1 (en) 2015-08-07 2016-08-04 A transglutamine tag for efficient site-specific bioconjugation

Country Status (9)

Country Link
US (1) US11130818B2 (enExample)
EP (1) EP3331904B1 (enExample)
JP (1) JP7008014B2 (enExample)
CN (1) CN107922479A (enExample)
AU (1) AU2016306907A1 (enExample)
CA (1) CA2994741A1 (enExample)
ES (1) ES2855998T3 (enExample)
IL (1) IL256810B (enExample)
WO (1) WO2017025179A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3419670A2 (en) * 2016-02-26 2019-01-02 Regeneron Pharmaceuticals, Inc. Optimized transglutaminase site-specific antibody conjugation
EP3272864A1 (en) * 2016-07-20 2018-01-24 Paul Scherrer Institut Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation
NZ762376A (en) 2017-09-19 2022-08-26 Scherrer Inst Paul Transglutaminase conjugation method and linker
HUE062089T2 (hu) * 2018-11-30 2023-09-28 Rao Naik Chetana Antitest, amely tartalmaz glutamintartalmú könnyû lánc C-terminális meghosszabbítást, annak konjugátumai, és eljárások és felhasználások
CA3128571A1 (en) 2019-03-19 2020-09-24 Paul Scherrer Institut Transglutaminase conjugation method with a glycine based linker
PL3865155T3 (pl) 2020-02-13 2023-01-30 Orano Med Sposób miejscowo-specyficznego modyfikowania przeciwciała
CN116406302A (zh) 2020-09-18 2023-07-07 阿拉里斯生物技术股份公司 用基于氨基酸的接头的谷氨酰胺转胺酶缀合方法
PE20231512A1 (es) 2020-10-25 2023-09-26 Araris Biotech Ag Medios y metodos para producir conjugados de ligador-anticuerpo
WO2023072934A1 (en) 2021-10-25 2023-05-04 Araris Biotech Ag Methods for producing antibody-linker conjugates
JP2025506650A (ja) * 2022-02-17 2025-03-13 レボロ バイオセラピューティクス リミテッド シャペロニン６０．１由来のペプチドを作製する方法
CN118742328A (zh) 2022-02-22 2024-10-01 阿拉里斯生物技术股份公司 包含两个或更多个有效载荷的肽接头
US20240337664A1 (en) * 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Characterization of crosslinking sites in antibody-drug conjugates
CN119744183A (zh) * 2023-07-31 2025-04-01 石药集团巨石生物制药有限公司 具有高药物负载的抗体-药物缀合物及其用途
WO2025082990A1 (en) 2023-10-15 2025-04-24 Araris Biotech Ag Antibody-drug conjugates using two different types of topoisomerase i inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6004528A (en) 1997-09-18 1999-12-21 Bergstein; Ivan Methods of cancer diagnosis and therapy targeted against the cancer stemline
DK1436003T3 (da) 2001-05-24 2010-03-15 Zymogenetics Inc TACI-immunoglobulin-fusionsproteiner
BRPI0410863A (pt) * 2003-05-30 2006-07-04 Centocor Inc formação de novos conjugados de eritropoietina usando transglutaminase
CA2552043A1 (en) * 2004-01-21 2005-08-04 Novo Nordisk A/S Transglutaminase mediated conjugation of peptides
CA2813411C (en) 2010-11-05 2016-08-02 Rinat Neuroscience Corporation Engineered polypeptide conjugates and methods for making thereof using transglutaminase
WO2013092998A1 (en) 2011-12-23 2013-06-27 Innate Pharma Enzymatic conjugation of antibodies
EP3086813B9 (en) 2013-12-23 2023-09-27 Covalab Mtg substrates for covalent conjugation of compounds
NZ742916A (en) * 2015-12-18 2023-03-31 Eisai R&D Man Co Ltd C-terminal lysine conjugated immunoglobulins

Also Published As

Publication number Publication date
IL256810B (en) 2021-10-31
AU2016306907A9 (en) 2019-07-25
EP3331904B1 (en) 2020-12-23
ES2855998T3 (es) 2021-09-27
US11130818B2 (en) 2021-09-28
WO2017025179A8 (en) 2018-04-19
IL256810A (en) 2018-03-29
CN107922479A (zh) 2018-04-17
EP3331904A1 (en) 2018-06-13
CA2994741A1 (en) 2017-02-16
JP2018529321A (ja) 2018-10-11
JP7008014B2 (ja) 2022-02-10
WO2017025179A1 (en) 2017-02-16
US20190194344A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
EP3331904B1 (en) A transglutamine tag for efficient site-specific bioconjugation
US10960083B2 (en) Binding protein drug conjugates comprising anthracycline derivatives
US20220111064A1 (en) Bi-specific antibodies for enhanced tumor selectivity and inhibition and uses thereof
CN108602878B (zh) C端赖氨酸缀合免疫球蛋白
AU2017279352B2 (en) Lysine conjugated immunoglobulins
Hong et al. Site-specific C-terminal dinitrophenylation to reconstitute the antibody Fc functions for nanobodies
US20190248907A1 (en) Anti-c-met antibodies and antibody drug conjugates thereof for efficient tumor inhibition
US20210317233A1 (en) Super Versatile Method for Imparting New Binding Specificity to Antibody
US20240190958A1 (en) Novel antibody drug conjugates with novel napi2b antibodies, therapeutic methods and uses thereof
EP3880254A1 (en) Polypeptide conjugates
KR20250090330A (ko) 신규한 항-tpbg 항체 및 이를 기반으로 한 항체-약물-접합체, 치료 방법 및 이의 용도
HK40090868A (zh) 含有糖基化fc结构域的蛋白质的位点特异性缀合的方法
CA3183906A1 (en) Methods for site specific conjugation of proteins containing glycosylated fc domains

Legal Events

Date Code Title Description
SREP Specification republished
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application